ArticleOncology research2017

The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.

Enrico Mini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.